MEDIA RELEASE

MELBOURNE, VIC – We’re pleased to share that Redenlab has been awarded $2.5 million in non-dilutive funding through the CUREator+ Dementia & Cognitive Decline incubator program. This support will allow us to further develop and scale our large language model (LLM)-powered platform, which uses speech biomarkers to better detect and monitor early signs of cognitive decline.   

In a recent update from the Australian Institute of Health and Welfare, dementia was reported as one of the leading causes of death in Australia. This underscores the urgent need for better tools for detection and monitoring. The timing of this funding is critical, as it enables us to advance technology that has the potential to make a real impact on the lives of people affected by dementia. 

This funding is a meaningful step forward in our work to improve how cognitive function is measured. Our clinically informed platform analyses subtle changes in speech, language and emotion to deliver objective, non-invasive assessments that can be completed remotely and at scale. We are focused on developing validated endpoints that can be deployed in health clinics, supporting earlier detection and improved clinical decision-making. 

“The CUREator+ scheme offers non-dilutive scale-up opportunities that are rarely seen in the biotech industry. We’re incredibly grateful to ANDHealth, Brandon Capitol and the Department of Health for the support and trust they have placed in our team. This funding allows us to build on years of scientific development and move closer to getting our technology in the hands of the consumer.”

Prof Adam Vogel, CEO of Redenlab 

The CUREator+ program is an initiative supported by the Australian Government’s Medical Research Future Fund (MRFF) and delivered by Brandon BioCatalyst, ANDHealth and Dementia Australia. Redenlab was one of seven companies selected through a national competitive process that considered scientific strength, commercial potential and community feedback from people with lived experience of dementia. 

“These companies are at the forefront of Australian innovation, developing therapeutics, medical devices and digital and connected health solutions, which have the potential to profoundly improve the lives of people living with dementia and cognitive decline.”

Bronwyn Le Grice, CEO of ANDHealth

Funding is provided in tranches tied to clear development milestones. As part of the program, high-performing awardees may be eligible to apply for additional top-up funding, creating further opportunity to extend and accelerate successful outcomes.

In addition to funding, the program offers commercialisation support, mentoring and access to networks that will help translate our research into practical clinical and research tools. 

We’re committed to advancing technology that makes a difference in people’s lives, and we look forward to the next stage of this work.

About Redenlab: 

Redenlab is a leading health technology company specialising in clinical speech analytics. With a mission to optimise decision-making in clinical trials and healthcare research, Redenlab leverages leading knowledge in communication and technology to measure and analyse speech patterns, providing valuable insights into brain health. Their clinical outcome assessments have led the field by changing how we identify and monitor disease. The technology is used by the world’s leading pharmaceutical and biotech companies across 25 countries and over 350 sites. 

For media inquiries, please contact: 

Gloria Macan 
Chief Marketing Officer 
Redenlab 
Gmacan@redenlab.com